530084-79-8

Basic information

• Product Name: 8-Benzyloxy-5-((R)-2-broMo-1-hydroxyethyl)-1H-quinolinone
• Synonyms: 8-benzyloxy-5((R)-2-broMo-1-hydroxyethyl)-2-(1H-)-quinolinone;(R)-8-Benzyloxy-5-(2-broMo-1-hydroxyethyl)carbostyril;5-(2-BroMo-(R)-1-hydroxyethyl)-8-benzyloxy-2(1H)-quinolinone;5-[(1R)-2-BroMo-1-hydroxyethyl]-8-(phenylMethoxy)-2(1H)-quinolinone;8-(Benzylox;(R)-8-(Benzyloxy)-5-(2-broMo-1-hydroxyethyl)quinolin-2(1H)-one;8-Benzyloxy-5((R)-2-broMo-1-hydroxyethyl)-2-(1H)-quinoline;8-Benzyloxy-5-((R)-2-broMo-1-hydroxyethyl)-1H-quinolin-2-one
• CAS NO: 530084-79-8
• Molecular Formula: C₁₈H₁₆BrNO₃
• Molecular Weight: 374.22854
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics
• Mol File: 530084-79-8.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 595.764 °C at 760 mmHg
• Flash Point: 314.107 °C
• Appearance: /
• Density: 1.491 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.649
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly)
• PKA: 10.78±0.70(Predicted)
• CAS DataBase Reference: 8-Benzyloxy-5-((R)-2-broMo-1-hydroxyethyl)-1H-quinolinone(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Benzyloxy-5-((R)-2-broMo-1-hydroxyethyl)-1H-quinolinone(530084-79-8)
• EPA Substance Registry System: 8-Benzyloxy-5-((R)-2-broMo-1-hydroxyethyl)-1H-quinolinone(530084-79-8)

Safety Data

• Hazardous Substances Data: 530084-79-8(Hazardous Substances Data)

Usage

Chemical Properties

Light Brown Solid

Uses

8-Benzyloxy-5-((R)-2-bromo-1-hydroxyethyl)-1H-quinolinone is used in the preparation of phenylethanolamine derivatives as β2 adrenoreceptor agonists.

InChI:InChI=1/C18H16BrNO3/c19-10-15(21)13-6-8-16(18-14(13)7-9-17(22)20-18)23-11-12-4-2-1-3-5-12/h1-9,15,21H,10-11H2,(H,20,22)/t15-/m0/s1

Upstream product

• 100331-89-3 8-benzyloxy-5-(2-bromoacetyl)-1H-quinolin-2-one 
• 64-18-6 formic acid 
• 15450-76-7 8-Hydroxy-1H-quinolin-2-one 
• 100-39-0 benzyl bromide 
• 57434-96-5 5-acetyl-8-hydroxyquinoline hydrochloride 
• 100331-93-9 5-Acetyl-8-benzyloxyquinoline-N-oxide 
• 26872-48-0 1-(8-benzyloxyquinolin-5-yl)ethanone 
• 2598-31-4 5-acetyl-8-hydroxyquinoline 
• 112022-83-0 (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole 
• 93609-84-8 5-acetyl-8-benzyloxy-1H-quinolin-2-one 
• 62978-73-8 5-acetyl-8-hydroxy-2(1H)-quinolinone 
• 15450-72-3 2-oxo-1,2-dihydroquinolin-8-yl acetate 
• 148-24-3 8-quinolinol 
• 1127-45-3 8-Hydroxyquinoline-N-oxide 

Downstream Products

• 1254097-58-9 4-({[5-(2-{[4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)phenyl]carbamoyl}ethyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254098-73-1 4-[({5-[(8-{[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}octyl)oxy]-2-phenylphenyl}carbamoyl)oxy]-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254098-93-5 4-({[5-(2-{[4-(2-{[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}-2-methylpropyl)phenyl]carbamoyl}ethyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254099-09-6 4-({[5-(9-{[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}nonyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254103-10-0 4-({[5-(9-[{(2R)-[8-(benzyloxy)-2-oxo-1,2-dihydroquinolin-5-yl]-2-hydroxyethyl}amino]nonyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254099-13-2 4-{[(5-{3-[(5-{[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pentyl)oxy]propyl}-2-phenylphenyl)carbamoyl]oxy}-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 530084-74-3 (R)-8-(benzyloxy)-5-(2-bromo-1-((tert-butyldimethylsilyl)oxy)ethyl)quinolin-2(1H)-one 
• 100429-06-9 8-benzyloxy-5-{(1R)-1-hydroxy-2-[N-((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino]ethyl}carbostyril 
• 1052689-06-1 8-benzyloxy-5-{(1R)-1-hydroxy-2-[N-((lR)-2-(p-methoxy phenyl)-1-methylethyl) amino] ethyl} carbostyril hydrochloride 
• 100429-08-1 8-hydroxy-5-((1R)-1-hydroxy-2-(N-((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride 
• 662111-65-1 8-benzyloxy-5-[(R)-2-benzylamino-1-hydroxyethyl]-(1H)-quinolin-2-one 
• 948895-02-1 8-(benzyloxy)-5-[(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-({[4-hydroxy-1-(4-phenoxybutyl)piperidin-4-yl]methyl}amino)ethyl]quinolin-2(1H)-one 
• 948895-60-1 5-((1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-{[(1-{2-[2-(2,6-dichlorophenyl)ethoxy]ethyl}-4-hydroxypiperidin-4-yl)methyl]amino}ethyl)-8-hydroxyquinolin-2(1H)-one 
• 948894-41-5 8-(benzyloxy)-5-{(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-[({4-methoxy-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methyl)amino]ethyl}quinolin-2(1H)-one 

Relevant articles and documents

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

The targeting of both the muscarinic and β-adrenergic pathways is a well validated therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In this communication we report our effort to incorporate two pharmacologies into a single chemical entity, whose characteristic must be suitable for a once daily inhaled administration. Contextually, we aimed at a locally acting therapy with limited systemic absorption to minimize side effects. Our lung-tailored design of bifunctional compounds that combine the muscarinic and β-adrenergic pharmacologies by the elaboration of the muscarinic inhibitor 7, successfully led to the potent, pharmacologically balanced muscarinic antagonist and β2 agonist (MABA) 13.

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmace